A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Akeso
- Target Recruit Count
- 100
- Registration Number
- NCT05559554
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Akeso
- Target Recruit Count
- 950
- Registration Number
- NCT05509361
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, China
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 36
- Registration Number
- NCT05505825
- Locations
- 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇦🇺Sunshine Hospital, St Albans, Victoria, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 48
- Registration Number
- NCT05504317
- Locations
- 🇨🇳
AkesoBio Investigative Site 1002, Bengbu, Anhui, China
🇨🇳AkesoBio Investigative Site 1001, Beijing, China
AK112 in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 398
- Registration Number
- NCT05499390
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Akeso
- Target Recruit Count
- 405
- Registration Number
- NCT05489289
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 125
- Registration Number
- NCT05467995
- Locations
- 🇨🇳
The first affiliated hospital of Bengbu medical college, Bengbu, Anhui, China
🇨🇳Peking university people's hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang hospital, Beijing, Beijing, China
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05432492
A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Akeso
- Target Recruit Count
- 36
- Registration Number
- NCT05393063
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 104
- Registration Number
- NCT05382442
- Locations
- 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China